Edition:
United Kingdom

Express Scripts Holding Co (ESRX.OQ)

ESRX.OQ on NASDAQ Stock Exchange Global Select Market

86.65USD
15 Aug 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$86.65
Open
--
Day's High
--
Day's Low
--
Volume
1
Avg. Vol
1,139,981
52-wk High
$86.85
52-wk Low
$55.80

Select another date:

Wed, Aug 15 2018

Photo

Express Scripts staking out million dollar gene therapies

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

CORRECTED--Express Scripts staking out million dollar gene therapies

Aug 15 Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

RPT-FOCUS-Express Scripts staking out million dollar gene therapies

Aug 15 Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Express Scripts staking out million-dollar gene therapies

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Express Scripts staking out million-dollar gene therapies

Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

FOCUS-Express Scripts staking out million dollar gene therapies

Aug 15 Express Scripts Holding Co built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Icahn reverses position on Cigna-Express Scripts deal

Activist investor Carl Icahn said on Monday that he no longer intended to solicit proxies to vote against the $52 billion Cigna-Express Scripts deal, a turn around from his position last week when he urged the health insurer's shareholders to vote against it.

Icahn reverses position on Cigna-Express Scripts deal

Activist investor Carl Icahn said on Monday that he no longer intended to solicit proxies to vote against the $52 billion Cigna-Express Scripts deal, a turn around from his position last week when he urged the health insurer's shareholders to vote against it.

UPDATE 1-Icahn reverses position on Cigna-Express Scripts deal

Aug 13 Activist investor Carl Icahn said on Monday that he no longer intended to solicit proxies to vote against the $52 billion Cigna-Express Scripts deal, a turn around from his position last week when he urged the health insurer's shareholders to vote against it.

Cigna-Express Scripts deal gets backing from another proxy firm

Aug 13 Cigna Corp said Glass Lewis & Co on Monday recommended its shareholders vote in favour for the proposed $52 billion acquisition of pharmacy benefits manager Express Scripts, the second proxy advisory firm to support the deal.

Select another date: